PAQ Therapeutics is a biotechnology startup established in 2020 and headquartered in the United States. The company is focused on revolutionizing healthcare and disease treatment through autophagy, a natural cellular degradation process. Its proprietary ATTEC (autophagosome-tethering compound) technology aims to create a new class of small molecule degraders capable of linking diverse substrates to the autophagy pathway. This includes proteins, aggregates, lipids, organelles, and pathogens, showcasing a wide-ranging potential for therapeutic applications.
PAQ Therapeutics recently secured a significant $30.00M Series A investment on 15 July 2021. The investment was led by a consortium of prominent investors including Matrix Partners China, Huagai Capital, MRL Ventures Fund, MSA Capital, Nest.Bio Ventures, and Sherpa Venture Capital. This influx of capital is poised to propel PAQ Therapeutics' cutting-edge research and development efforts in degradation therapies, potentially reshaping the landscape of drug discovery and development.
The company operates within the Biotechnology and Health Care industries, positioning itself as a pioneering force in advancing the understanding and application of autophagy for improved health outcomes.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $30.00M | 6 |
|
15 Jul 2021 |
No recent news or press coverage available for PAQ Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
